Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.
Division of Urology, Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
PLoS One. 2024 Aug 7;19(8):e0306900. doi: 10.1371/journal.pone.0306900. eCollection 2024.
Non-metastatic castration-resistant prostate cancer (nmCRPC) is an asymptomatic condition with the potential to progress to metastasis. Novel hormonal agents (NHAs) are currently considered the gold standard treatment for nmCRPC, offering significant survival benefits. However, further evidence is needed to determine whether there are differences in the performance of these drugs among Asian populations.
This retrospective analysis of nmCRPC patients aims to compare the efficacy and safety of three NHAs-apalutamide, darolutamide, and enzalutamide. Data were collected from two prominent prostate care centers in Taichung, Taiwan. Patient characteristics, treatment details, PSA responses, and adverse events were analyzed. Statistical comparisons were performed, and the study received Institutional Review Board approval.
Total of 64 patients were recruited in this study, including 29 darolutamide, 26 apalutamide, and 9 enzalutamide patients. Baseline characteristics varied between the three patient groups, but the treatment response still revealed similar results. The apalutamide group experienced more adverse events, notably skin rash. Discontinuation rates due to adverse events differed among the groups, and patients receiving darolutamide were less likely to discontinue treatment.
This real-world study provides insights into NHA utilization in nmCRPC within the Taiwanese population. Adverse event profiles varied, emphasizing the need for individualized treatment decisions. The study underscores the importance of regional considerations and contributes valuable data for optimizing treatment outcomes in nmCRPC.
非转移性去势抵抗性前列腺癌（nmCRPC）是一种无症状的疾病，有进展为转移的潜在风险。新型激素药物（NHAs）目前被认为是 nmCRPC 的金标准治疗方法，提供了显著的生存获益。然而，需要进一步的证据来确定这些药物在亚洲人群中的表现是否存在差异。
本项针对 nmCRPC 患者的回顾性分析旨在比较三种新型激素药物（阿帕他胺、达罗他胺和恩扎卢胺）的疗效和安全性。数据来自中国台湾台中市的两家著名前列腺护理中心。分析了患者特征、治疗细节、PSA 反应和不良事件。进行了统计学比较，该研究获得了机构审查委员会的批准。
本研究共纳入 64 例患者，包括 29 例达罗他胺、26 例阿帕他胺和 9 例恩扎卢胺患者。三组患者的基线特征存在差异，但治疗反应仍显示出相似的结果。阿帕他胺组发生更多的不良事件，特别是皮疹。由于不良事件而停药的发生率在各组之间存在差异，接受达罗他胺治疗的患者停药的可能性较小。
本真实世界研究提供了关于新型激素药物在台湾人群中治疗 nmCRPC 的应用见解。不良事件谱存在差异，强调需要个体化治疗决策。该研究强调了区域考虑的重要性，并为优化 nmCRPC 的治疗结果提供了有价值的数据。
